DMA1 Antibody

What is the DM1A antibody and what does it target?

DM1A is a mouse monoclonal [IgG1] antibody that specifically targets alpha-tubulin, a major constituent of microtubules . Alpha-tubulin forms heterodimers with beta-tubulin to create microtubules, which are essential cytoskeletal components. The DM1A antibody recognizes tubulin alpha-1b with an observed molecular weight of 50-55 kDa . This antibody is extensively validated and has been cited in over 1,220 publications, making it one of the most reliable tools for tubulin research .

What experimental applications is the DM1A antibody validated for?

The DM1A antibody has been validated for multiple research applications:

• Western blotting (WB): Functions as an excellent loading control due to consistent alpha-tubulin expression across various experimental conditions

• Immunocytochemistry/Immunofluorescence (ICC/IF): Effectively labels microtubule structures with high specificity

• Immunohistochemistry (IHC-P): Successful detection in formalin-fixed, paraffin-embedded tissues including human and rat colon

• Flow cytometry: Effective for intracellular staining in methanol-fixed/Tween-permeabilized cells

This versatility makes it an indispensable tool for researchers studying cytoskeletal dynamics and using alpha-tubulin as a reference protein.

What species reactivity does the DM1A antibody demonstrate?

DM1A shows confirmed reactivity with human, mouse, rat, and canine alpha-tubulin . Based on the high sequence conservation of tubulin across species, it is predicted to also recognize alpha-tubulin from chicken, guinea pig, hamster, cow, pig, Xenopus laevis, gerbil, and African green monkey . This broad cross-reactivity makes DM1A particularly valuable for comparative studies across different model organisms and validation of findings across species.

What are the optimal experimental conditions for using DM1A antibody in Western blotting?

For Western blotting applications, researchers have reported successful results with the following conditions:

• Protein loading: 20μg of total protein lysate is sufficient for strong signal detection

• Incubation conditions: Overnight incubation at 4°C following a total protein stain yields clear bands at the expected size

• Dilution factor: Effective at 1:2000 dilution for Western blotting applications

• Detection systems: Compatible with both chemiluminescence and fluorescence-based detection (e.g., Licor secondary antibody and imaging system)

Multiple researchers have independently verified these conditions, confirming the antibody produces clean, strong bands with minimal background when properly optimized .

How does DM1A antibody affect microtubule structure and dynamics when used in live cell applications?

The DM1A antibody has specific effects on microtubule structures that researchers should consider when designing live-cell experiments. Upon binding to alpha-tubulin, DM1A causes 10 nm filaments to collapse into large lateral aggregates that localize either at the cell periphery or in tight juxtanuclear caps . Importantly, it does not block the fundamental process of microtubule assembly, nor does it inhibit polymerization or depolymerization of platelet tubulin in vitro .

What factors should researchers consider when using DM1A antibody as a loading control for quantitative protein analysis?

When employing DM1A as a loading control for quantitative analysis, researchers should consider several technical factors:

• Signal linearity range: Alpha-tubulin's high abundance can lead to signal saturation at higher protein concentrations. Researchers should establish a calibration curve to ensure measurements fall within the linear detection range.

• Treatment effects on cytoskeleton: While one verified researcher noted DM1A is "not affected by treatments, therefore reliable loading control" , experimental interventions specifically targeting cytoskeletal components might alter alpha-tubulin levels. Control experiments should verify stability under specific experimental conditions.

• Tissue-specific expression variations: Alpha-tubulin expression levels vary between tissues and cell types. When comparing different tissues, these variations should be considered when normalizing target protein levels.

• Potential post-translational modifications: Various modifications of tubulin can affect antibody recognition, potentially influencing quantification in certain experimental contexts.

• Technical reproducibility: Multiple researchers have reported consistent results with DM1A across different detection systems , suggesting high technical reproducibility when protocols are properly followed.

How can researchers distinguish between DM1A binding to free tubulin dimers versus polymerized microtubules?

Distinguishing between DM1A binding to free tubulin dimers versus polymerized microtubules requires specific experimental approaches:

• Differential centrifugation: By separating soluble (free dimers) and insoluble (polymerized) tubulin fractions using ultracentrifugation, researchers can quantify DM1A binding to each fraction via Western blotting.

• Conformation-specific co-staining: Using antibodies that preferentially recognize polymerized tubulin (such as those against acetylated tubulin) alongside DM1A can help differentiate populations.

• In vitro polymerization assays: Comparing DM1A binding to purified tubulin before and after induced polymerization can reveal binding preferences.

• Fluorescence microscopy with co-localization analysis: High-resolution imaging can distinguish between the diffuse cytoplasmic signal (free dimers) and filamentous patterns (polymerized microtubules).

• Microtubule-stabilizing or -destabilizing treatments: Treating cells with agents like taxol (stabilizing) or nocodazole (destabilizing) before DM1A staining can help characterize its binding preferences under different polymerization states.

The epitope recognized by DM1A appears to remain accessible in both conformational states, but quantitative differences in binding affinity may exist that could be exploited for experimental purposes.

What are the most effective fixation and permeabilization protocols for DM1A in immunofluorescence studies?

Based on research reports, the following fixation and permeabilization protocols have proven effective for DM1A in immunofluorescence applications:

• PFA fixation: 4% paraformaldehyde fixation of mouse spinal cord tissues yielded strong labeling with DM1A at 1:50 dilution .

• Methanol fixation: For cultured cells, methanol fixation combined with Tween permeabilization has been validated for flow cytometry applications .

• Cross-linking fixatives: Formaldehyde-based fixation preserves cellular architecture while maintaining the DM1A epitope accessibility.

• Combination approaches: Sequential fixation with aldehydes followed by methanol can preserve both structural integrity and antigen recognition.

The choice of protocol may depend on the specific experimental question, with cross-linking fixatives better preserving cellular architecture and organic solvents sometimes providing superior epitope accessibility. Researchers should validate the optimal protocol for their specific cell type and experimental design.

How can researchers troubleshoot common issues with DM1A antibody performance?

When encountering problems with DM1A antibody performance, researchers can implement the following troubleshooting strategies:

• Weak or absent signals:

  • Increase antibody concentration (validated working dilutions range from 1:50 for IHC to 1:2000 for WB)

  • Extend primary antibody incubation time (overnight at 4°C is effective for WB)

  • Verify sample preparation (ensure complete protein denaturation for WB)

  • Check for protein degradation (use fresh lysates or add protease inhibitors)

• High background:

  • Increase blocking time or concentration (5% BSA or milk proteins)

  • Add additional washing steps with increased detergent concentration

  • Decrease primary antibody concentration

  • Use alternative blocking agents (e.g., fish gelatin or normal serum)

• Non-specific bands in Western blot:

  • Optimize sample preparation (ensure complete reduction of disulfide bonds)

  • Increase gel resolution (use longer gels or gradient gels)

  • Perform peptide competition assays to confirm specificity

• Poor reproducibility:

  • Standardize protein extraction methods

  • Implement strict quality control for all reagents

  • Document exact protocol conditions

  • Consider lot-to-lot variation in antibody production

Multiple researchers have reported clear, strong bands for DM1A in Western blot applications , suggesting that with proper optimization, high performance can be achieved.

What distinguishes DM1A antibody from other alpha-tubulin antibodies in research applications?

The DM1A antibody offers several distinct advantages compared to other alpha-tubulin antibodies:

• Extensive validation: With citations in over 1,220 publications , DM1A has been rigorously validated across numerous experimental systems and applications.

• Well-characterized epitope behavior: DM1A's epitope accessibility is maintained under various fixation and experimental conditions , making it versatile for multiple applications.

• Defined effect on microtubule dynamics: Unlike some antibodies that may completely disrupt microtubule structure, DM1A causes specific aggregation patterns without blocking assembly , enabling certain functional studies.

• Broad species cross-reactivity: The ability to recognize alpha-tubulin across multiple species facilitates comparative studies and validation across different model organisms.

• Performance as loading control: Multiple researchers have confirmed its reliability as a loading control even under various experimental treatments , establishing it as a reference standard in the field.

These characteristics have contributed to DM1A's status as a benchmark antibody for tubulin research, against which newer antibodies are often compared.

How does the DM1A antibody relate to the Dma1 protein studied in yeast systems?

Despite the similarity in nomenclature, the DM1A antibody and the Dma1 protein are entirely distinct entities:

The DM1A antibody is a mouse monoclonal antibody targeting alpha-tubulin protein . It serves as a laboratory research tool for detecting and studying tubulin in experimental systems.

In contrast, Dma1 is a checkpoint protein in fission yeast (Schizosaccharomyces pombe) that functions as a ubiquitin ligase . It regulates mitotic progression by delaying mitotic exit and cytokinesis when kinetochores are not properly attached to the mitotic spindle . Dma1 accomplishes this by ubiquitinating Sid4, a scaffold protein of the septation initiation network .

Key molecular features of Dma1 include:

• Requirement for dimerization for proper function, with specific residues in the C-terminal tail being critical

• Regulation by Dnt1, which acts as a negative regulator in early mitosis

• Varying localization to spindle pole bodies according to cell cycle stage

The similarity in names is coincidental and should not be confused when interpreting scientific literature.

How do DM1-containing antibody-drug conjugates relate to DM1A antibody applications in research?

DM1-containing antibody-drug conjugates (ADCs) and the DM1A antibody represent distinct applications of molecular biology:

The DM1A antibody is a research tool for detecting alpha-tubulin in laboratory applications , with no therapeutic purpose.

In contrast, DM1 (maytansinoid 1) is a cytotoxic agent used in ADCs like trastuzumab-DM1 (T-DM1) . In these therapeutic applications, DM1 is conjugated to antibodies targeting specific antigens on cancer cells, such as HER2. After binding and internalization, DM1 is released intracellularly, where it inhibits microtubule assembly by binding to tubulin, leading to cell cycle arrest and apoptosis .

Interestingly, both entities interact with tubulin biology through different mechanisms:

• DM1A binds to alpha-tubulin as a detection tool

• DM1 in ADCs disrupts tubulin function as a cytotoxic mechanism

This connection highlights how fundamental research tools like DM1A contribute to our understanding of cellular processes that can be targeted therapeutically with technologies like ADCs.

How should researchers design control experiments when using DM1A antibody for novel cell types or experimental conditions?

When adapting DM1A antibody use to novel cell types or experimental conditions, researchers should implement comprehensive control strategies:

• Positive controls:

  • Include previously validated cell lines (e.g., HeLa, HEK293, NIH3T3) alongside novel samples

  • Run purified tubulin as a standard for molecular weight verification

  • Compare results with established protocols before extending to novel conditions

• Negative controls:

  • Perform staining without primary antibody to assess secondary antibody specificity

  • Use cells with tubulin knockdown (siRNA) to verify signal specificity

  • Employ peptide competition assays to confirm epitope specificity

• Cross-validation approaches:

  • Compare DM1A results with another validated alpha-tubulin antibody targeting a different epitope

  • Correlate immunostaining patterns with GFP-tubulin in transfected cells

  • Verify subcellular localization patterns match expected microtubule distribution

• Validation across techniques:

  • Confirm consistent molecular weight by Western blotting before interpreting immunofluorescence in novel cell types

  • Compare quantification results across multiple detection methods (fluorescence vs. chemiluminescence)

• Optimization variables to test:

  • Titrate antibody concentration for each new application (1:50 to 1:2000 range)

  • Test multiple fixation protocols (crosslinking vs. precipitating fixatives)

  • Vary incubation conditions (temperature, duration, buffer composition)

These systematic controls ensure reliable interpretation of results when extending DM1A use to new experimental systems.

What considerations are important when designing multiplex immunofluorescence studies that include DM1A antibody?

Designing effective multiplex immunofluorescence studies with DM1A requires careful consideration of several factors:

• Antibody compatibility:

  • DM1A is a mouse IgG1 isotype , requiring selection of co-staining antibodies from different species or isotypes to avoid cross-reactivity

  • If using multiple mouse antibodies, consider directly conjugated primary antibodies or sequential immunostaining protocols

• Spectral separation:

  • Select fluorophores with minimal spectral overlap for each target

  • Account for the abundant nature of tubulin when balancing fluorescence intensities

  • Consider the subcellular distribution of targets (microtubules have a distinctive pattern)

• Fixation optimization:

  • Identify fixation protocols compatible with all target epitopes

  • PFA fixation (4%) has been validated for DM1A in tissue samples

  • Methanol fixation with Tween permeabilization works for cultured cells

• Order of antibody application:

  • Apply antibodies against less abundant targets before DM1A if using sequential protocols

  • Consider light sensitivity and stability of fluorophores when planning staining sequence

• Image acquisition settings:

  • Optimize exposure settings individually for each channel

  • Implement controls for bleed-through and cross-excitation

  • Consider the three-dimensional nature of the microtubule network in imaging and analysis

• Validation strategies:

  • Perform single-staining controls alongside multiplex protocols

  • Include biological controls with known co-localization patterns

  • Validate antibody performance in multiplex conditions against single-plex standards

These considerations will help ensure accurate interpretation of multiplex studies incorporating DM1A antibody.

How can researchers effectively use DM1A antibody in studies of tubulin post-translational modifications?

For investigating tubulin post-translational modifications (PTMs) in conjunction with DM1A antibody, researchers should implement the following strategies:

This systematic approach enables researchers to study the complex landscape of tubulin PTMs while maintaining accurate quantification through DM1A-based normalization.

How does research on Dma1 in yeast inform our understanding of checkpoint mechanisms in human diseases?

Research on Dma1 in fission yeast provides valuable insights into checkpoint mechanisms relevant to human diseases:

Dma1 functions in a mitotic checkpoint pathway that delays cytokinesis when kinetochores are not properly attached to the mitotic spindle . Mechanistically, it ubiquitinates the scaffold protein Sid4, which antagonizes Polo-like kinase (Plo1) activity and prevents mitotic exit under checkpoint conditions . Several findings from Dma1 research have implications for human disease:

• Conservation of checkpoint mechanisms: Dma1 is identified as a potential functional relative of the human tumor suppressor Chfr , suggesting evolutionary conservation of checkpoint regulation. Dysfunction in checkpoint mechanisms is a hallmark of cancer and other proliferative disorders.

• Regulatory mechanisms: The discovery that Dnt1 inhibits Dma1 in early mitosis reveals how precise temporal control of checkpoint proteins is achieved. This has parallels in human diseases where dysregulated checkpoint proteins contribute to pathogenesis.

• Dimerization requirement: Studies showing that Dma1 dimerization is essential for its function highlight a potential regulatory mechanism that might be conserved in human ubiquitin ligases. Targeting protein dimerization could represent a therapeutic strategy.

• Cell cycle-dependent localization: Dma1's concentration at spindle pole bodies varies throughout the cell cycle , demonstrating how spatial regulation contributes to checkpoint function. Disrupted protein localization is often observed in disease states.

These findings provide conceptual frameworks and experimental approaches that can be applied to studying human checkpoint proteins, potentially revealing new therapeutic targets for diseases involving mitotic dysregulation.

What are the implications of antibody-drug conjugate technology for targeting tubulin dynamics in cancer therapy?

Antibody-drug conjugate (ADC) technology leveraging tubulin-targeting payloads has significant implications for cancer therapy:

Trastuzumab-DM1 (T-DM1), which combines the HER2-targeting antibody trastuzumab with the microtubule-disrupting agent DM1 , demonstrates the therapeutic potential of targeting tubulin dynamics. This approach has several key implications:

• Enhanced therapeutic index: By delivering tubulin-targeting agents specifically to cancer cells, ADCs can achieve higher local drug concentrations while minimizing systemic toxicity. Engineered variants like thio-trastuzumab-mpeo-DM1 show further improved therapeutic indexes .

• Overcoming resistance mechanisms: Novel linker designs can bypass resistance mechanisms like multidrug transporters. For example, conjugates prepared with hydrophilic PEG4Mal linker showed better efficacy against MDR1-expressing tumors than those using non-polar SMCC linker .

• Exploiting cancer vulnerabilities: Cancer cells are particularly sensitive to disruption of tubulin dynamics due to their rapid proliferation rate. ADCs leverage this vulnerability while sparing most normal cells through targeted delivery .

• Expanding the application of tubulin-targeting agents: Many potent tubulin-targeting compounds have limited clinical utility due to toxicity, but ADC technology can potentially resurrect these compounds by improving their therapeutic window.

• Combination therapy potential: ADCs like T-DM1 retain the mechanistic properties of their antibody component (e.g., HER2 signaling inhibition) while adding the cytotoxic effect of the payload , enabling dual-mechanism targeting.

These advantages have led to active development of numerous tubulin-targeting ADCs, potentially expanding treatment options for patients with limited therapeutic alternatives.

How can researchers leverage alpha-tubulin antibodies for studying neurological disorders involving cytoskeletal dysfunction?

Alpha-tubulin antibodies like DM1A offer valuable tools for investigating neurological disorders with cytoskeletal components:

Microtubules are essential for neuronal function, involved in neurite outgrowth, axonal transport, and synaptic plasticity. Many neurological disorders involve cytoskeletal disruptions, making alpha-tubulin antibodies crucial research tools. Researchers can leverage these antibodies through several approaches:

• Pathological specimen analysis:

  • Compare tubulin organization and post-translational modifications between healthy and diseased tissues

  • Quantify neuronal microtubule density using DM1A as a baseline marker

  • Correlate alterations in microtubule architecture with disease progression

• Disease model characterization:

  • Assess cytoskeletal changes in cellular and animal models of neurodegeneration

  • Monitor real-time tubulin dynamics in response to stress conditions

  • Evaluate the impact of disease-associated mutations on microtubule stability

• Therapeutic screening applications:

  • Use DM1A-based assays to identify compounds that stabilize neuronal microtubules

  • Develop high-content screening platforms to assess microtubule-modulating drugs

  • Evaluate microtubule-targeting therapies in neurodegenerative disease models

• Mechanistic investigations:

  • Study the interaction between disease-related proteins and microtubules

  • Investigate how pathological protein aggregates affect microtubule dynamics

  • Examine the role of tubulin post-translational modifications in disease pathogenesis

• Diagnostic development:

  • Explore tubulin modifications as potential biomarkers for disease detection

  • Develop quantitative assays for specific tubulin isoforms associated with pathology

  • Implement automated image analysis of cytoskeletal architecture for diagnostic purposes

By combining DM1A with other cytoskeletal markers and advanced imaging techniques, researchers can gain deeper insights into the cytoskeletal basis of neurological disorders and identify new therapeutic targets.